Evidence memo / Longevity & metabolic aging

Pinealon

Also: Glu-Asp-Arg peptide · EDR peptide · pineal short peptide

Pinealon is a synthetic three-amino-acid peptide from the Russian short-peptide bioregulator research program, studied mainly in cells and animals for antioxidant and neuroprotective effects. The published work comes largely from a single research group, with little independent replication and no rigorous human trials. The Watchlist boundary is keeping this to its laboratory status and not treating brain-protection and anti-aging marketing as established benefit.

No human data yetPreclinicalSafety / regulatory watch

The verdict

Our read at a glance.

Whether pinealon's antioxidant and neuroprotective effects in laboratory models support the brain-health and anti-aging claims made for it.

The signal
In cell and animal studies, mostly from one research program, pinealon has been reported to reduce oxidative stress and protect neurons. This evidence is preclinical, comes with limited independent replication, and there are no rigorous human trials establishing benefit.
The unknown
Whether any of the laboratory effects occur in people, since the human evidence is essentially absent and the existing studies have not been widely reproduced.
Our read
A laboratory peptide with thin, largely single-source evidence and no human trials. Pinealon's antioxidant and neuroprotective reports are preclinical and not well replicated, so brain-health and anti-aging claims run well ahead of the data.

The mechanism

How it works.

Pinealon is a synthetic three-amino-acid peptide (Glu-Asp-Arg) from the Russian short-peptide bioregulator program. Its developers propose that, because it is so small, it can enter cells and reach DNA, where it is said to bind regulatory regions and shift the activity of genes tied to antioxidant defense and neuron survival, reducing oxidative damage and protecting nerve cells. This mechanism is inferred from a narrow body of cell and animal studies, mostly from one research group, and has not been shown to do anything measurable in people.

Safety & regulatory boundary

The consequential part.

Pinealon is not an approved drug and has not been tested in rigorous human trials. Products sold under this name are unapproved research chemicals of uncertain identity and purity. Marketing it for brain protection or anti-aging makes human claims that the laboratory evidence does not support.

What's next

What we're watching.

Whether any independent group reproduces the neuroprotective findings, and whether the compound is ever tested in a controlled human study.

Context

Why this is discussed.

It is marketed as a tiny peptide that protects brain cells and slows aspects of aging, which appeals to people interested in cognition and longevity.

The evidence base

9 cited references.

Keep reading

Related published memos.